Melissa Frost
Psychiatric/Mental Health · Auburn, CANPI 1952337800
Payments from drug & device makers
Across 187 payments — averaging $53.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$6K
- AbbVie$1K
- Intuitive Surgical$684
- Alkermes, Inc.$556
- Neurocrine Biosciences, Inc.$373
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$292
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$4,98750%
- Travel & lodging$7828%
- Food & beverage$4,12141%
- Education$1181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $5,580 |
| AbbVie | 66 | $1,312 |
| Intuitive Surgical | 4 | $684 |
| Alkermes, Inc. | 14 | $556 |
| Neurocrine Biosciences, Inc. | 12 | $373 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $292 |
| Johnson & Johnson | 8 | $203 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $187 |
| Lundbeck LLC | 11 | $184 |
| Teva Pharmaceuticals USA, Inc. | 6 | $169 |
| Bausch Health US, LLC | 9 | $163 |
| Neuronetics, Inc. | 3 | $146 |
| Sunovion Pharmaceuticals Inc. | 4 | $83 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $30 |
| Indivior Inc. | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$4,987
- LYBALVI$1,322
- Da Vinci Surgical System$646
- INGREZZA$136
- CAPLYTA$124
How this compares
$10,008 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 27 | $421,454 |
| IngrezzaValbenazine Tosylate | 29 | $303,266 |
| Austedo XrDeutetrabenazine | 13 | $186,663 |
| VraylarCariprazine Hcl | 62 | $104,407 |
| RexultiBrexpiprazole | 20 | $39,774 |
| CaplytaLumateperone Tosylate | 19 | $30,668 |
| BelsomraSuvorexant | 24 | $12,303 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,076 |
| Aripiprazole | 77 | $5,542 |
| Doxepin Hcl | 26 | $4,204 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 55 | $4,090 |
| Duloxetine Hcl | 74 | $2,469 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 79 | $2,160 |
| Bupropion XlBupropion Hcl | 90 | $2,156 |
| Quetiapine Fumarate | 136 | $1,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $169 | $608,11740 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $373 | $303,26629 claims |
| AbbVieVraylar | $1,312 | $104,40762 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $5,580 | $39,77420 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $292 | $30,66819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $187 | $9,07624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Auburn
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.